NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised $176.18 million across 7 funding rounds and went public on NASDAQ in May 2021.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on addressing high unmet medical needs in central nervous system (CNS) diseases. The company develops medicines for conditions such as severe bipolar depression with suicidality and post-traumatic stress disorder (PTSD). Its pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors. NRx Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving patients and providers globally.

Strategic signal

In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics completed the acquisition of Dura Medical, marking an initial step in establishing a network of interventional psychiatry clinics. This strategic acquisition signals NRx Pharmaceuticals' expansion beyond drug development into direct patient care infrastructure, aiming to integrate its therapeutic solutions more broadly within the mental health treatment landscape.

Company Intelligence Q&A

What was a significant recent regulatory achievement for NRx Pharmaceuticals?

In September 2025, NRx Pharmaceuticals secured FDA Fast Track designation for its IV Ketamine formulation, NRX-100, for suicidal depression. This designation aims to expedite the development and review of the therapy.

What strategic acquisition did NRx Pharmaceuticals' subsidiary complete?

In September 2025, NRx Pharmaceuticals' subsidiary HOPE Therapeutics, Inc. completed the acquisition of Dura Medical. This acquisition represents an initial step in building a network of interventional psychiatry clinics.

What was the outcome of NRx Pharmaceuticals' FDA suitability petition?

In September 2025, NRx Pharmaceuticals received notification of US Food and Drug Administration approval of a suitability petition for its proposed strength of preservative-free ketamine.

What was a key development regarding NRx Pharmaceuticals' NRX-100 product in September 2024?

In September 2024, NRx Pharmaceuticals announced the completion of twelve months of stability testing on the first manufactured commercial scale lot of NRX-100 (Ketamine).

What was NRx Pharmaceuticals' activity in October 2024 regarding clinic acquisitions?

In October 2024, HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. announced the signing of a Letter of Intent to acquire its first Florida Interventional Psychiatry Clinics, following a similar announcement for a West Coast clinic earlier that month.